The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer

Hyuna Sung1, Ji-Yeob Choi1,6, Sang-Ah Lee2, Kyoung-Mu Lee3, Sohee Han4, Sujee Jeon5, Minkyo Song4, Yunhee Lee1, Sue K Park1,4,6, Keun-Young Yoo4, Dong-Young Noh6,7, Sei-Hyun Ahn8 and Daehee Kang1,4,6*

Abstract
Background: Although a number of experimental studies have suggested the role of lipocalin-2 (LCN2) and matrix metalloproteinase-9 (MMP-9) in breast cancer progression, limited numbers of epidemiological studies have examined the relationship between the levels of lipocalin-2 and MMP-9 and breast cancer survival.

Methods: Preoperative serum levels of lipocalin-2 and MMP-9 were measured in 303 breast cancer patients and 74 healthy controls recruited between 2004 and 2007. We examined the association between lipocalin-2 and MMP-9 levels and disease-free survival (DFS) using Cox proportional hazard regression model.

Results: The serum levels of lipocalin-2 and MMP-9 were not significantly different between patients and controls (P > 0.05). Elevated lipocalin-2 and MMP-9 levels were associated with reduced DFS of breast cancer (P_trend = 0.029 and P_trend = 0.063, respectively). When lipocalin-2 and MMP-9 levels were categorized based on the combined risk score, patients with higher levels of both lipocalin-2 and MMP-9 exhibited poor DFS compared to patients with lower levels (P_trend = 0.004). Furthermore, these effects were profound in patients with BMI less than 25 kg/m^2 (adjusted hazard ratio (aHR), 3.17; 95% confidence intervals (CI), 1.66-6.06, P_trend < 0.001) or lymph-node negative breast cancer (aHR, 5.36; 95% CI, 2.18-13.2, P_trend < 0.001).

Conclusions: Our study suggests that the elevated levels of lipocalin-2 and MMP-9 are associated with reduced breast cancer survival, particularly in patients with lower BMI and lymph-node negative breast cancers.

Background
While breast cancer incidence has increased over the 30–40 years, mortality has remained stable or has even decreased in the last 10–15 years, probably contributed to earlier detection and improved treatment strategy as well [1,2]. Considering the substantial increase in breast cancer survivors, to identify prognostic factors associated with recurrence and survival is more important today ever than before after primary treatment. Although commonly available prognostic factors include pathology criteria such as lymph-node status, tumor size, histologic grade and estrogen receptor (ER) status, these factors do not predict accurately exact clinical outcome probably due to heterogeneity of breast cancers. While numerous studies support the prognostic relevance of circulating tumor marker such as CA 15–3, CA 27, CA 29, CEA and tissue based multiparameter gene expression assays, it is not yet sufficient to support routine use in clinical practice [3].

Lipocalin-2, also known as neutrophil gelatinase-associated lipocalin (NGAL), is a 25 kDa secretory glycoprotein belonging to the lipocalin superfamily to act as transporter of small hydrophobic substances [4]. Initially known only as an antibacterial factor of innate immunity, lipocalin-2 has been suggested to participate in diverse biological processes such as, inflammation, acute organ damage, lipid metabolism, and cancer development. Particularly, lipocalin-2 has gained attention as a potential biomarker and a modulator of several types of human cancers, thus a potential therapeutic target as well [5].
Although the mechanisms are not clearly elucidated, several studies suggest possible mechanisms underlying the role of lipocalin-2 in mammary tumor initiation and progression [6].

Human lipocalin-2 was originally isolated in the complex with matrix metalloproteinase-9 (MMP-9), a zinc dependent proteolytic enzyme involved in the degradation of many different constituents of basement membranes and subsequent remodeling of extracellular matrix [7,8]. In preclinical model and in clinical samples, it was demonstrated that lipocalin-2 could protect the degradation of MMP-9 by forming the lipocalin-2/MMP-9 complex, which can enhance the enzymatic activity of MMP-9 and facilitate the tumor growth through promoting its invasion of adjacent tissues or metastasis to distal organs [9-11]. Not only the key roles of MMP-9 in tumorigenesis but also their characteristics of being secreted into the blood stream have inspired many researchers to evaluate the associations between circulating level of MMP-9 and clinicopathological characteristics of breast cancers. However, majority of these studies were merely designed to investigate the correlation between clinical characteristics or disease status and circulating levels of MMP-9.

Along with the previous report that the enzymatic activity of urinary MMP-9/lipocalin-2 complex is detected in the urine of breast cancer patients but not in healthy control [11], several studies have suggested that circulating MMP-9, lipocalin-2 and MMP-9/lipocalin-2 complex could serve as a diagnostic and/or a prognostic biomarker in a variety of diseases with different suggested mechanisms [12-15]. In breast cancer, only one study has reported the positive association between the serum level of lipocalin-2/MMP-9 complex and disease status [16]. However, no other prior studies have examined the relationship between the circulating level of lipocalin-2 and MMP-9 and their combined effects on the prognosis of breast cancer.

Given the findings that both lipocalin-2 and MMP-9 are mainly secreted into the normal breast ducts and by neutrophils that have infiltrated into the tumor sites [17], we hypothesized that the serum levels of lipocalin-2 and MMP-9 might represent the aggressiveness of breast cancer and might be an independent prognostic factor of breast cancer survival. In the present study, we examined the association between preoperative serum levels of lipocalin-2 and MMP-9 and disease-free survival (DFS) and determined the potential of both proteins as noninvasive biomarkers in predicting the recurrence of breast cancer.

Methods
Study population
A total of 1,899 histologically confirmed incident breast cancer cases were recruited in the Seoul National University Hospital and Asan Medical Center between 2004 and 2007 [18]. Healthy women were recruited from a general hospital to visit for a regular health check-up in the same catchment area for breast cancer cases. After excluding the patients with history of cancer, age frequency matched women (N = 74) were selected and included in the analysis. At the time of interview, before any adjuvant chemotherapy and/or surgery, peripheral blood were collected and processed for the DNA extraction and serum separation. For the 925 of the patients, peripheral blood were collected into 10-ml serum storage tubes and were centrifuged at 3000 g for 10 minutes at room temperature. Serum were stocked in 0.3-ml aliquots in cryovials and stored at −80°C until the time of measurement.

After excluding the subjects with inadequate follow-up information, about 40% (N = 370) of subjects were selected. A retrospective chart review was used to collect clinical information and pathologic features including cancer stage based on 6th AJCC classification, tumor size, lymph-node invasion, distant organ metastasis, histologic grade, nuclear grade, estrogen receptor (ER) and progesterone receptor (PR) status, nuclear grade, histologic grade, surgical treatment and medical adjuvant therapy (adjuvant chemotherapy, radiation therapy, and hormone receptor therapy). Those with prehistory of cancer, multi-cancer at diagnosis, distant organ metastasis at diagnosis, and in situ breast cancer were additionally excluded. Thus, a total of 303 invasive ductal carcinoma cancer patients diagnosed with stage I-IIIC who underwent curative resection were included for final analysis.

Informed consents were received from every patient when the questionnaire was administered. The study design was approved by the Committee on Human Research of Seoul National University Hospital (IRB No. H-0503-144-004).

Serum lipocalin-2 and MMP-9 assays
The serum levels of proteins were determined using the Quantikine® Human Lipocalin-2/NGAL Immunoassay kit (R&D Systems, Minneapolis, MN, USA) and Human MMP-9 ELISA Kit (Bender MedSystem, Vienna, Austria) according to the manufacturer’s instruction. Reproducibility within the assay was evaluated with an intra-assay coefficient of variation of 3.7% for lipocalin-2 and 7.3% for MMP-9, respectively. The specificity was confirmed by testing its cross-reactivity with human recombinant COX-2, lipocalin-1, MMP-9 and mouse recombinant lipocalin-2. No significant cross-reactivity or interference was observed other than recombinant human MMP-9 /NGAL complex shows approximately 0.3% cross reactivity in this assay. The minimum detectable dose (MDD) was defined as the analyte concentration resulting in an absorbance significantly higher than that of the dilution medium (mean plus 2 standard deviations (SD)). The mean MDD of lipocalin-2 and MMP-9 was
0.012 ng/ml and 0.05 ng/ml, respectively (mean of independent assays).

Statistical analyses

The serum levels of lipocalin-2 and MMP-9 between cases and controls were compared by non-parametric Wilcoxon signed rank test and Student’s t-test. The distributions of lipocalin-2 and MMP-9 according to demographic factors and clinicopathological variables were compared by using Mantel-Haenszel chi-square test for categorical variables and Pearson correlation coefficients test for continuous variables. Since the levels of lipocalin-2 and MMP-9 were not normally distributed (the Kolmogorov–Smirnov test, \( P < 0.10 \), log square transformed values were used for correlation tests and survival analyses.

DFS was defined as the time from date of surgery to the date of the first locoregional recurrence, first distant metastasis, 2nd primary cancer or death from any cause. Patients known to be alive with no evidence of disease were censored at the last follow-up date.

Cox’s proportional hazard regression models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI). The proportional hazard assumption of the Cox model was examined by graphic evaluation of Schoenfeld residual plot. The multivariate model included TNM stage (I, IIA-IIB, and IIIA-IIIIC), ER status, and radiation therapy (yes and no). We included BMI (< 25 kg/m² and ≥ 25 kg/m²) as well due to the significant association between lipocalin-2 and BMI groups. Other covariates considered but not included the final model were age (< 39, 40–49, and ≥ 50), menopausal status, lymph-node status, tumor size, histologic grade (I-II and III), nuclear grade (I-II and III), PR status, adjuvant chemotherapy and hormone receptor therapy. Because these variables did not alter HRs significantly after adjusting for other covariates (statistical significance was set at \( P < 0.05 \)) and the full model adjusted for all covariates made no substantial difference to the results compared to the reduced model. We conducted analysis with lipocalin-2 and MMP-9 as continuous variables and as categorical variables in tertiles based on the distributions of cases.

To further assess the combined effects of both markers, we generated an equation, combined risk score = \( \exp [(0.054 \times \log \text{square transformed values of lipocalin-2}) + (0.024 \times \log \text{square transformed values of MMP-9})] \), based on the linear regression model using the coefficients of each marker determined by the multivariate model including each marker (continuous) and adjustment variables. The range of combined score was 1.092 to 14.276. The subjects were categorized into tertiles based on the distribution of the combined score: low (1.092-3.463), medium (3.464-4.997) and high (4.998-14.276) score groups. Wald \( P \) values for trend were computed by treating the tertiles or combined score groups as ordinal variable.

Additionally, stratified analyses were performed according to age group, menopausal status, BMI group, stage, tumor size, lymph-node status and ER/PR status. We tested for heterogeneity between strata by including product term of marker and stratification variable of interest in regression model.

To evaluate the predictive accuracy of serum biomarkers, receiver operating characteristic (ROC) curve and the area under the curve (AUC) were analyzed. In addition, to assess the internal validity of our model, we used k-fold cross-validation method using the entire dataset as both for development and validation of the model [19].

All statistical procedures were conducted using SAS version 9.2 (SAS Institute, Cary, NC) and STATA version 11.2 (Statacorp, College Station, TX). All \( P \) values reported were two-sided.

Results

The baseline characteristics of 303 breast cancer cases and 74 age and sex matched controls were described in Additional file 1: Table S1. The distributions of age and BMI were not different between cases and controls. Figure 1 shows the distribution of lipocalin-2 and MMP-9 in cases and controls. The levels of both markers were not significantly different between groups although the means of lipocalin-2 and MMP-9 of cases were slightly higher than those of controls (98.8 ± 81.7 vs. 93.0 ± 29.9 ng/ml for lipocalin-2 and 70.5 ± 64.3 vs. 62.8 ± 55.1 ng/ml, respectively).

After a median follow-up of 4.2 years (range, 0.2-5.3 years) there were 87 DFS events including 10 deaths from any cause among all 303 patients. Table 1 summarized univariate and multivariate–adjusted HRs for DFS by patients’ characteristics. Most patients were premenopausal (63.3%) and had BMI less than 25 kg/m² (75.6%). In multivariate analysis, TNM stage, ER status and radiation therapy were remained as independent and significant prognostic factors for DFS (\( P < 0.05 \)).

There was significant correlation between serum levels of lipocalin-2 and MMP-9 (\( r_{\text{pearson}} = 0.267; P < 0.001 \)). Table 2 shows the distributions of patients’ characteristics according to tertiles of lipocalin-2 and MMP-9. Women with higher lipocalin-2 levels were more likely to be heavier compared with women with low lipocalin-2 levels (\( P_{\text{trend}} = 0.054 \)). No other significant association was found between lipocalin-2 and MMP-9 and clinicopathological characteristics.

Table 3 shows the stage-, ER status-, BMI, and radiation therapy-adjusted HRs for DFS by lipocalin-2 and MMP-9 levels in overall patients. The elevated serum levels of lipocalin-2 and MMP-9 were significantly
associated with poor DFS, respectively and in combination. The adjusted HR for the 3 categories of lipocalin-2 were 1.96 (95% CI, 1.12-3.43) for the second tertile and 1.93 (95% CI, 1.07-3.47) for the third tertile compared with first tertile as reference group ($P_{\text{trend}} = 0.029$).

The similar but marginally significant relationship was observed for the association between MMP-9 and DFS (adjusted HR for third vs. first tertile 1.70; 95% CI 0.97-2.99; $P_{\text{trend}} < 0.001$), but no significant association was found in patients with a BMI more than 25 kg/m$^2$ ($P_{\text{interaction}} = 0.031$). A more significant and profound association was found in lymph-node negative patients with an adjusted HR of 5.36 (95% CI, 2.18-13.2; $P < 0.001$; $P_{\text{trend}} < 0.001$) than in lymph-node positive patients ($P_{\text{interaction}} = 0.094$). However, the associations between the score group and DFS were not different by age group, tumor size, histologic grade, nuclear grade, and hormone receptor status ($P_{\text{interaction}} > 0.10$) (data not shown).

**Discussion**

In the present study, we found that patients with elevated lipocalin-2 or MMP-9 levels at diagnosis had poorer DFS than patients with low lipocalin-2 or MMP-9 levels. Women with a high level of lipocalin-2 (> 59.03 ng/ml) and MMP-9 (> 34.42 ng/ml) had significantly increased risk for recurrence or death than women with a low level of each protein. In addition, patients with both markers in high levels showed significantly poor DFS, especially in the women with low BMI or lymph-node negative breast cancer.

Although Noh et al. suggested the lymphovascular invasion, poorer histologic grade and higher nuclear grade are associated with poor DFS in Korean breast cancer cases in recently published paper [20], histologic grade and nuclear grade were not independently associated with DFS in our subjects. There could be several reasons for this varied survival profile such as relatively shorter follow-up period of our study, different baseline characteristics of study population and definition of outcome of both studies, and uncontrolled bias from method of tumor assessment.

Several studies investigated the serum level of lipocalin-2 and MMP-9 not only in patients with diseases but also in healthy controls. The previous observational studies have shown that the mean or median baseline value of lipocalin-2 is highly contradictory dependent on the study design and assay method [21,22]. The normal range of lipocalin-2 measured...
Table 1 Hazard ratios for disease-free survival of breast cancer

|                  | All patients (N = 303) | Event (N = 87) | Crude HR (95% CI) | P      | Adjusted HR* (95% CI) | P      |
|------------------|------------------------|----------------|-------------------|--------|-----------------------|--------|
|                  | N (% )                 | N (% )        |                   |        |                       |        |
| FU duration (median), days | 67-1930 (1540)         | 67-1930 (1161) |                   |        |                       |        |
| Age, mean (SD)   | 46.6 (10.7)            | 46.5 (11.4)   | 0.99 (0.79-1.23)  | 0.897  | 1.00 (0.98-1.02)       | 0.911  |
| < 39             | 81 26.7                | 25 28.7       | 1.00              |        |                       | 1.00   |
| 40-49            | 108 35.6               | 29 33.3       | 0.85 (0.50-1.46)  | 0.557  | 1.21 (0.68-2.16)       | 0.525  |
| 50 ≤             | 114 37.7               | 33 37.9       | 0.83 (0.49-1.41)  | 0.496  | 0.97 (0.54-1.76)       | 0.926  |
| Menopausal statusb |                       |               |                   |        |                       |        |
| Premenopausal    | 191 63.3               | 54 62.1       | 1.00              |        | 1.00                  |        |
| Postmenopausal   | 111 36.8               | 33 37.9       | 1.02 (0.66-1.58)  | 0.915  | 1.01 (0.62-1.64)       | 0.982  |
| BMI, mean (SD)   | 23.3 (3.17)            | 23.5 (3.39)   |                   |        |                       |        |
| < 25 kg/m²       | 229 75.6               | 62 71.3       | 1.00              |        | 1.00                  |        |
| ≥ 25 kg/m²       | 74 24.4                | 25 28.7       | 1.11 (0.70-1.77)  | 0.665  | 1.10 (0.66-1.81)       | 0.723  |
| TNM stage        |                        |               |                   |        |                       |        |
| I                | 115 38                 | 18 20.7       | 1.00              |        | 1.00                  |        |
| II -IIIA         | 123 40.5               | 36 41.4       | 1.89 (1.06-3.37)  | 0.031  | 1.46 (0.78-2.73)       | 0.242  |
| II -IIIB         | 65 21.5                | 33 37.9       | 3.97 (2.20-7.13)  | <.0001 | 4.41 (2.27-8.57)       | <.0001 |
| Tumor size       |                        |               |                   |        |                       |        |
| < 2 cm           | 159 52.5               | 26 29.9       | 1.00              |        | 1.00                  |        |
| ≥ 2 cm           | 144 47.5               | 61 70.1       | 2.78 (1.74-4.44)  | <.0001 | 2.42 (1.46-4.02)       | <.0001 |
| Lymph node status |                      |               |                   |        |                       |        |
| Negative         | 170 56.1               | 40 46         | 1.00              |        | 1.00                  |        |
| Positive         | 133 43.9               | 47 54         | 1.54 (1.27-1.86)  | <.0001 | 1.47 (0.93-2.31)       | 0.092  |
| Histologic gradeb |                       |               |                   |        |                       |        |
| I-II             | 160 55.4               | 32 39         | 1.00              |        | 1.00                  |        |
| III              | 129 44.6               | 50 61         | 2.11 (1.35-3.30)  | 0.001  | 1.36 (0.81-2.28)       | 0.248  |
| Nuclear gradeb   |                        |               |                   |        |                       |        |
| I-II             | 145 54.6               | 33 39.8       | 1.00              |        | 1.00                  |        |
| III              | 133 45.4               | 50 60.2       | 1.96 (1.26-3.06)  | 0.003  | 1.16 (0.70-1.95)       | 0.564  |
| ER status        |                        |               |                   |        |                       |        |
| Positive         | 173 57.1               | 36 41.4       | 1.00              |        | 1.00                  |        |
| Negative         | 130 42.9               | 51 58.6       | 2.40 (1.56-3.70)  | <.0001 | 2.34 (1.46-3.75)       | <.0001 |
| PR status        |                        |               |                   |        |                       |        |
| Positive         | 159 52.5               | 33 37.9       | 1.00              |        | 1.00                  |        |
| Negative         | 144 47.5               | 54 62.1       | 2.19 (1.41-3.39)  | 0.001  | 1.45 (0.79-2.65)       | 0.235  |
| Adjuvant chemotherapyb |                  |               |                   |        |                       |        |
| Yes              | 216 72.7               | 74 87.1       | 1.00              |        | 1.00                  |        |
| No               | 81 27.3                | 11 12.9       | 0.34 (0.17-0.65)  | 0.001  | 0.61 (0.26-1.41)       | 0.249  |
| Radiation therapyb |                    |               |                   |        |                       |        |
| Yes              | 184 61.7               | 49 57.7       | 1.00              |        | 1.00                  |        |
| No               | 114 38.3               | 36 42.4       | 1.26 (0.81-1.94)  | 0.310  | 2.08 (1.24-3.49)       | 0.006  |

*Adjusted for age, BMI, menopausal status, tumor and node stage, tumor size, lymph node status, and menopausal status

bPremenopausal vs. Postmenopausal

Sung et al. BMC Cancer 2012, 12:193
http://www.biomedcentral.com/1471-2407/12/193
through our study (42.7-187.1 ng/ml) was comparable to the range suggested by Porta et al. (47–177 ng/ml) [23,24]. However, Choi et al. suggested the normal range as 43.8 ± 27.8 ng/ml which is much lower than our data (93.0 ± 29.9 ng/ml) [25]. Similarily the previous reports on the serum level of MMP-9 in healthy controls are highly contradictory [16,26]. Although with a small sample size, Provatopoulou et al. demonstrated a marked increase in serum concentration of lipocalin-2 and MMP-9 for women with invasive ductal carcinoma compared with the healthy controls. This inconsistency across the studies might be caused mainly due to the method of sample collection (timing, storage, and preparation etc.), detection method and uncontrolled potential confounding factors related to patients’ characteristics. Furthermore, several factors related to the biochemical characteristics of each marker could have disturbed the concentrations of serum proteins such as the coagulation and fibrinolysis factor and leukocyte degraulation [27]. In addition, given the sample size of our study, the standard deviation is too large, especially for both markers measured in cases, to obtain enough power to compare the concentrations between cases and controls. Thus our results should be interpreted with cautions and need to be confirmed in larger sample size. For this reason, we evaluated the variables based on the distribution of cases samples rather than to define the normal range of lipocalin-2.

In a previous study using tissue microarray containing samples from 207 breast cancer patients, elevated expression of lipocalin-2 correlates with some indicators of a phenotype severity including a low ER/PR expression, a low grade of differentiation, the presence of lymph-node metastases and a high Ki-67 proliferation index, and overexpressed lipocalin-2 is associated with poor DFS consistent with our results using serum [17,28,29].

Table 1 Hazard ratios for disease-free survival of breast cancer (Continued)

| Hormone receptor therapy | No | Yes |
|--------------------------|----|-----|
|                         |    |     |
| Yes                      | 198| 66.2|
|                         |    |     |
| No                       | 101| 33.8|

a Adjusted for BMI (< 25 and ≥ 25 kg/m²), TNM stage (I, II, and III), ER status (positive and negative) and radiation therapy (yes and no).

b Adjusted for BMI (< 25 and ≥ 25 kg/m²), lymph node status (yes and no), ER status (positive and negative) and radiation therapy (yes and no).

c Adjusted for BMI (< 25 and ≥ 25 kg/m²), tumor size (< 2 and ≥ 2 cm), ER status (positive and negative) and radiation therapy (yes and no).

HR, hazard ratio; CI, confidence interval; BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor.

Table 2 The distributions of demographic and clinicopathological characteristics according to tertile of lipocalin-2 and MMP-9 in all patients

| Lipocalin-2 (ng/ml) | MMP-9 (ng/ml) |
|---------------------|--------------|

| t1 | t2 | t3 | P<sub>trend</sub> | t1 | t2 | t3 | P<sub>trend</sub> |
|----|----|----|------------------|----|----|----|------------------|
| (2.63-59.03) | (59.03-109.65) | (109.65-772.34) | (0.15-34.42) | (34.42-80.36) | (80.36-397.09) | |

| Age, mean (SD) | 46.5 (11.6) | 47.3 (10.6) | 45.9 (9.9) | 0.67<sup>b</sup> | 48.2 (10.5) | 44.4 (9.8) | 47.1 (11.5) | 0.58<sup>b</sup> |
|----------------|-------------|-------------|-------------|------------------|-------------|-------------|-------------|------------------|
| Premenopausal status, % | 65.0 | 60.4 | 64.4 | 0.93 | 53.0 | 72.6 | 64.0 | 0.11 |
| BMI < 25 kg/m², % | 82.0 | 74.5 | 70.3 | 0.05 | 77.0 | 78.4 | 71.3 | 0.35 |
| TNM stage, % | | | | | | | | |
| I | 32.0 | 40.2 | 41.6 | 0.59 | 35.0 | 46.1 | 32.7 | 0.72 |
| II–III | 48.0 | 39.2 | 34.7 | 0.39 | 39.0 | 35.3 | 47.5 | 0.72 |
| IIIA–IIIC | 20.0 | 20.6 | 23.8 | 0.26 | 26.0 | 18.6 | 19.8 | 0.35 |
| Tumor size < 2 cm, % | 46.0 | 53.9 | 57.4 | 0.11 | 47.0 | 62.8 | 47.5 | 0.95 |
| Lymph-node negative, % | 57.0 | 54.9 | 56.4 | 0.94 | 55.0 | 60.8 | 52.5 | 0.72 |
| Histologic grade I-II, % | 48.9 | 61.2 | 55.7 | 0.36 | 48.4 | 62.2 | 55.2 | 0.35 |
| Nuclear grade I-II, % | 51.6 | 58.0 | 54.1 | 0.73 | 52.1 | 57.0 | 54.6 | 0.72 |
| ER positive, % | 56.0 | 59.8 | 55.5 | 0.94 | 53.0 | 61.8 | 56.4 | 0.63 |
| PR positive, % | 51.0 | 54.9 | 51.5 | 0.95 | 48.0 | 58.8 | 50.5 | 0.73 |
| Adjuvant chemotherapy Yes, % | 75.8 | 66.7 | 75.8 | 0.99 | 74.2 | 70.0 | 74.0 | 0.98 |
| Radiation therapy Yes, % | 62.2 | 58.0 | 65.0 | 0.69 | 67.7 | 60.6 | 57.0 | 0.12 |
| Hormone receptor therapy Yes, % | 63.6 | 69.0 | 66.0 | 0.73 | 62.6 | 70.0 | 66.0 | 0.61 |

a Mantel-Haenszel chi-square test.
b Pearson correlation coefficients test.
The relationship between high levels of lipocalin-2 being detected in clinical samples of different tumor types, especially in epithelial origin tumors, such as esophageal [30], gastric [31], ovarian [32], pancreatic cancers [33] with clinical outcomes are being published. However, the precise source of serum lipocalin-2 has remained controversial. It is plausible that the overexpressed lipocalin-2 in tumor tissue released into the circulation may contribute to the elevated systematic level of lipocalin-2 supported by the direct correlation between elevated serum levels of lipocalin-2 and strong immunostaining grade in gastric tumor cells [34]. In addition, as an acute-phase protein, lipocalin-2 may be released into the plasma from activated neutrophils, macrophages, and other immune cells in various inflammatory conditions [35,36].

Recent findings suggest possible mechanisms underlying lipocalin-2 function in tumorigenesis, such as promoting the epithelial-mesenchymal transition (EMT) [29], regulating the iron homeostasis in cancer cells, affecting on steroid-dependent tumor growth and modulating MMP-9 activity [6]. When lipocalin-2 is complexed with MMP-9, there is enhancement of the active MMP-9 pool [9]. The cooperative role between lipocalin-2 and MMP-9 in breast cancer progression prompted us to investigate the concomitant presence of MMP-9 and we found the positive correlation between lipocalin-2 and MMP-9 in serum from breast cancer patients. Although several reports suggest that elevated serum levels of MMP-9 occur in serum and plasma of breast cancer patients [37-42], correlation with current clinical parameters and association with clinical outcome are still controversial mainly due to different types of samples being assayed and sampling procedures [27].

Furthermore, we observed the prognostic value is further intensified in certain subgroups. We found stronger and significant association in patients with a BMI less than 25 kg/m². When we examined this association with a median value of BMI, the similar pattern was also observed although \( P \) for interaction was marginally significant. This finding may be partly explained by the fact that, among patients with a BMI less than 25 kg/m², there was

Table 3 Multivariate–adjusted hazard ratios for disease-free survival of lipocalin-2 and MMP-9

|                      | No. of total patients (N=303) | No. of events (N=87) | Adjusted HR\(^a\) (95% CI) | \( P \) |
|----------------------|-------------------------------|----------------------|-----------------------------|--------|
| Lipocalin-2 continuous | 1.06 (1.02-1.09)              | 0.001                |
| (ng/ml) t1           | 1.00 (reference)              | 1.00 (reference)     |
| t2                   | 1.96 (1.12-3.34)              | 0.018                |
| t3                   | 1.93 (1.07-3.47)              | 0.028                |
| \( P_{\text{trend}} \) | 1.36 (1.03-1.79)              | 0.029                |
| MMP-9 continuous      | 1.02 (0.99-1.06)              | 0.136                |
| (ng/ml) t1           | 1.00 (reference)              | 1.00 (reference)     |
| t2                   | 1.95 (1.12-3.39)              | 0.018                |
| t3                   | 1.70 (0.97-2.99)              | 0.065                |
| \( P_{\text{trend}} \) | 1.28 (0.99-1.67)              | 0.063                |
| Combined score\(^b\) | low                           | 1.00 (reference)     |
|                      | medium                        | 1.55 (0.88-2.74)     | 0.130 |
|                      | high                          | 2.22 (1.29-3.84)     | 0.004 |
| \( P_{\text{trend}} \) | 1.49 (1.14-1.95)              | 0.004                |

\(^a\) Adjusted for BMI (< 25 and \( \geq 25 \) kg/m²), TNM stage (I, II, and III), ER status (positive and negative) and radiation therapy (yes and no).

\(^b\) The subjects were categorized into three groups based on the tertiles of combined score: low (1.092-3.463), medium (3.464-4.997) and high (4.998-14.276) score groups.

Figure 2 The ROC curve of the final model. The naïve model was fitted with Cox proportional hazard regression model using combined score (continuous) adjusted for BMI (< 25 and \( \geq 25 \) kg/m²), TNM stage (I, II, and III), ER status (positive and negative) and radiation therapy (yes and no). The prediction error fitted ROC was estimated using 10-fold cross validation. Among the 303 patients, 298 subjects were used in ROC analysis since the subjects with missing values of any covariates were excluded.
significant difference in lipocalin-2 levels between patients alive without recurrence and patients who had recurrence ($P < 0.05$). Given that obesity at diagnosis of breast cancer has been associated with an increased risk of recurrence and death [43,44], it is possible that the impact of lipocalin-2 level and/or combined score on DFS could only be demonstrated in the lower BMI group, with these markers being independent prognostic factors of breast cancer. In lymph-node negative breast cancer patients, the high score group was associated with a 5.36 fold increased risk compared with low score group. However, because of wide 95% CIs in these categorical analyses, these results should be interpreted with caution. Yet the 95% CIs became narrower when examining analyses between ordinal value of risk group and DFS (HR, 2.21; 95% CI 1.45-3.35; $P < 0.001$). Our study has several limitations. We collected and measured both markers in a single manner, thus could not completely characterize the profiles of both markers accompanied by treatment response and subsequent survival. In addition, due to the relatively short term follow-up time, we could not assess the relationship between both markers and long term survival related to mortality of breast cancer. Thus these results must be interpreted cautiously and need to be confirmed in independent and large number of subjects to evaluate the external validity.

Our study has several limitations. We collected and measured both markers in a single manner, thus could not completely characterize the profiles of both markers accompanied by treatment response and subsequent survival. In addition, due to the relatively short term follow-up time, we could not assess the relationship between both markers and long term survival related to mortality of breast cancer. Thus these results must be interpreted cautiously and need to be confirmed in independent and large number of subjects to evaluate the external validity.

### Table 4 Hazard ratios for disease-free survival and the combined risk scores of serum lipocalin-2 and MMP-9 levels according to BMI and lymph node status

| Combined score | No. of total patients (N=303) | No. of events (N=87) | Adjusted HR$^b$ (95% CI) | $P$ | $P_{\text{interaction}}$ |
|---------------|-------------------------------|----------------------|---------------------------|-----|-------------------------|
| **BMI < 25** |                               |                      |                           |     |                         |
| t1            | 81                            | 17                   | 1.00 (reference)          | 0.031 |                         |
| N=229         | t2                            | 77                   | 20                        | 1.74 (0.88-3.42) | 0.110 |                     |
|               | t3                            | 71                   | 25                        | 3.17 (1.66-6.06) | <.0001 |                     |
|               | $P_{\text{trend}}$            |                      |                           | 1.78 (1.29-2.46) | <.0001 |                     |
| **BMI ≥ 25** |                               |                      |                           |     |                         |
| t1            | 20                            | 13                   | 1.00 (reference)          |     |                         |
| N=74          | t2                            | 23                   | 15                        | 0.92 (0.27-3.08) | 0.886 |                     |
|               | t3                            | 31                   | 21                        | 0.92 (0.32-2.63) | 0.881 |                     |
|               | $P_{\text{trend}}$            |                      |                           | 0.96 (0.57-1.62) | 0.891 |                     |
| **LN –**      |                               |                      |                           |     |                         |
| t1            | 57                            | 9                    | 1.00 (reference)          | 0.094 |                         |
| N=170         | t2                            | 55                   | 12                        | 3.28 (1.19-9.07) | 0.022 |                     |
|               | t3                            | 58                   | 19                        | 5.36 (2.18-13.2) | <.0001 |                     |
|               | $P_{\text{trend}}$            |                      |                           | 2.21 (1.45-3.35) | <.0001 |                     |
| **LN +**      |                               |                      |                           |     |                         |
| low           | 44                            | 29                   | 1.00 (reference)          |     |                         |
| N=133         | medium                        | 45                   | 29                        | 1.31 (0.64-2.68) | 0.462 |                     |
| high          | 44                            | 28                   | 1.43 (0.69-2.95)          | 0.335 |                         |
| $P_{\text{trend}}$ |                      |                     |                           | 1.20 (0.84-1.71) | 0.328 |                     |

a The subjects were categorized into three groups based on the tertiles of combined score: low (1.092-3.463), medium (3.464-4.997) and high (4.998-14.276) score groups.

b Adjusted for BMI ($<25$ and $\geq 25$ kg/m$^2$), TNM stage (I, II, and III), ER status (positive and negative) and radiation therapy (Yes and No). For stratified analysis by BMI group, the stratification variable of interest (BMI) was not included as covariate in the model.

LN –, lymph-node negative; LN +, lymph-node positive.
Conclusions
In conclusion, to our knowledge, this is the only study that has evaluated the prognostic role of preoperative serum lipocalin-2 and combined effect of lipocalin-2 and MMP-9 in patients with operable breast cancer suggesting that the elevated levels of lipocalin-2 and MMP-9 are associated with reduced breast cancer survival.

Additional file

Additional file 1: Table S1. Serum levels of lipocalin-2 and MMP-9 were compared between breast cancer cases (N = 303) and age and sex matched healthy controls (N = 74). Table S2. The predictive accuracy of model using combined score of Lipocalin-2 and MMP-9 and other prognostic factors.

Acknowledgement
Grant support: This work was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology [2011–0027212].

Author details
1Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea. 2Department of Preventive Medicine, Kangwon National University School of Medicine, Kangwon, Korea. 3Department of Environmental Health, Korea National Open University, Seoul, Korea. 4Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea. 5Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Korea. 6Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. 7Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. 8Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.

Received: 21 August 2011 Accepted: 14 May 2012
Published: 28 May 2012

References
1. Hery C, Ferlay J, Boniol M, Autier P. Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol 2008, 19:1187–1194.
2. Hery C, Ferlay J, Boniol M, Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol 2008, 19:1099–1018.
3. Harris L, Fritzsch H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287–5312.
4. Bolignano D, Donato V, Lacquinti A, Fazio MR, Bono C, Crippolino G, Ruemi M. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett 2010, 288:10–16.
5. Yang J, Moses MA. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle 2009, 8:2347–2352.
6. Leng X, Wu Y, Arlinghaus RB. Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol 2011, 226:309–314.
7. Treibel S, Blaser J, Reinke H, Tschesche H. A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 1992, 314:386–388.
8. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993, 268:10425–10432.
9. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001, 276:37258–37265.
10. Tschesche H, Zolzer V, Treibel S, Barsch S. The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. Eur J Biochem 2001, 268:1818–1828.
11. Fernandez CA, Yan L, Louis G, Yang J, Kukut J, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 2005, 11:5390–5395.
12. Tsai HT, Su PH, Lee TH, Tee YT, Lin LY, Yang SF, Wang PH. Significant elevation and correlation of plasma neutrophil gelatinase associated lipocalin and its complex with matrix metalloproteinase-9 in patients with pelvic inflammatory disease. Clin Chim Acta 2011, 412:1252–1256.
13. Gupta K, Shukla M, Cowland JB, Malemud CJ, Haqiq TM. Neutrophil gelatinase-associated lipocalin is expressed in osteoarthrits and forms a complex with matrix metalloproteinase 9. Arthritis Rheum 2007, 56:3326–3335.
14. Diamanti-Kandarakis E, Livaditi S, Kandarakis SA, Mangeli A, Papassotiriou I. Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? Eur J Endocrinol 2008, 158:525–531.
15. Smith ER, Zurakowski D, Saaid A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 2008, 14:2578–2586.
16. Provatasoulou X, Gounaris A, Kalogera E, Zagouri F, Fliess I, Gouretsis E, Nonni A, Papassotiriou I, Zogafos G. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer 2009, 9:390.
17. Stoessl SP, Friedl A, Haag JD, Lindstrom MJ, Clark GM, Gould MN. Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer 1998, 79:565–572.
18. Han S, Lee KM, Choi JY, Park SK, Lee JY, Lee JE, Noh DY, Ahn SH, Han W, Kim DH, et al. CASP8 polymorphisms, estrogen and progesterone receptor status, and breast cancer risk. Breast Cancer Res Treat 2008, 110:387–393.
19. Venweij PJ, Van Houwelingen HC. Cross-validation in survival analysis. Stat Med 1993, 12:2305–2314.
20. Noh JM, Choi DH, Huh SJ, Park W, Yang JH, Nam SJ, Jin YH, Ahn JS. Patterns of recurrence after breast-conserving treatment for early stage breast cancer by molecular subtype. J Breast Cancer 2011, 14:46–51.
21. Choi KM, Kim TN, Yoo HJ, Lee KW, Cho GJ, Hwang TG, Baik SH, Choi DS, Kim SM: Effect of exercise training on A-FABP, lipocalin-2 and RBP4 levels in obese women. Clin Endocrinol (Oxf) 2009, 70:569–574.
22. Malyszko J, Malyszko JS, Pawlak K, Myśliwiec M. NGAL (neutrophil gelatinase-associated lipocalin) is a new and sensitive marker of kidney function in renal allograft recipients. Transplant Int 2007, 20:240–240.
23. Porta C, Paglino C, De Amici M, Quaglini S, Sacchi L, Imarisio I, Canipari C. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 2010, 77:809–815.

Abbreviations
aHR: Adjusted hazard ratio; BMI: Body mass index; CI: Confidence intervals; DFS: Disease-free survival; EMT: Epithelial-mesenchymal transition; ER: Estrogen receptor; HR: Hazard ratio; LCN2: Lipocalin-2; MDD: Minimum detectable dose; LN: Lymph-node negative; LN+; Lymph-node positive; MMP-9: Matrix metalloproteinase-9; NGAL: Neutrophil gelatinase-associated lipocalin; PR: Progesterone receptor; SD: Standard deviations.
24. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A: Accuracy of neutrophil gelatinate-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009, 54:1012–1024.

25. Choi KM, Lee JS, Choi DS, Oh DJ, Park CG: Implication of lipocalin-2 and vistatin levels in patients with coronary heart disease. Eur J Endocrinol 2008, 158:203–207.

26. Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, Xu XC: Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 2008, 122:1920–2056.

27. Mannello F, Tonti GA: Gelatinase concentrations and zymographic profiles in human breast cancer: matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: the coagulation/fibrinolysis pathways after the release, activation and recovery of different gelatinases in serum. Int J Cancer 2007, 121:216–218. author reply 219–223.

28. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A: Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 2008, 108:389–397.

29. Sabo E, Meitner PA, Tavares R, Corless CL, Lauwers GY, Moss SF, Resnick MB: Expression analysis of Barrett’s esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue. Clin Cancer Res 2008, 14:6440–6448.

30. Cubben FJ, Sier CF, Tschescche H, van Duijn W, Zuidwijk K, van der Reijden JJ, Hanemaaijer R, Griffioen G, Lamers CB, Verspaget HW: Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer 2007, 43:1869–1876.

31. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Golden M, Dunn D, Roman JJ, et al: Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 2004, 112:14–25.

32. terris B, Baievi E, Cimogalar-Jurcivic T, Jones M, Missaglia E, Ruszniewski P, Sauvanet A, Lemoine NR: Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 2002, 160:1745–1754.

33. Wang HJ, He XJ, Ma YY, Jiang XT, Xia YJ, Ye YZ, Zhao ZS, Tao HQ: Expressions of neutrophil gelatinase-associated lipocalin in gastric cancer: a potential biomarker for prognosis and an ancillary diagnostic test. Anat Rec (Hoboken) 2010, 293:1855–1863.

34. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK: The neutrophil lipocalin (NGAL) is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002, 10:1033–1043.

35. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A: Lipocalin 2 mediates an innate immune response to bacterial infection by sequestering iron. Nature 2004, 432:917–921.

36. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, Shriver CD: Circulating MMP2 and MMP9 in breast cancer – potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 2006, 119:1403–1411.

37. Decock J, Hendrickx W, Wildiers H, Christiaens MR, Neven P, Drijkoningen M, Paridaens R: Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/new expression and other clinicopathological variables. Clin Exp Metastasis 2005, 22:495–502.

38. Talvernaati-Martilla A, Turpeenniem-Hujanen T: Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma. Cancer Lett 2005, 217:237–242.

39. Somiari SB, Shriver CD, Heckman CM, Olsen C, Hu H, Jordan R, Arciero C, Russell S, Garigulio G, Hooke J, Somiari RI: Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast cancer, breast cancer and at risk of developing breast cancer. Cancer Lett 2006, 233:98–107.

40. Patel S, Sumrana G, Koner BC, Saxena A: Role of serum matrix metalloproteinase-2 and –9 to predict breast cancer progression. Clin Biochem 2011, 44:869–872.

41. La Rocca G, Pucci-Malinafa I, Marrazzo A, Taormina P, Malinafa S: Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004, 90:1414–1421.

42. Kroenke CH, Chen WY, Rosner B, Holmes MD: Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 2005, 23:1370–1378.

43. Chlebowski RT, Aiello E, McTieman A: Weight loss in breast cancer patient management. J Clin Oncol 2002, 20:1128–1134.

44. Rosen PR, Grossen S, Salgo PE, Kinne DW, Hellman S: A long-term follow-up study of survival in stage I (TNM0) and stage II (TNM0) breast carcinoma. J Clin Oncol 1989, 7:355–366.

45. Hs Ch, Taib NA, Tan GT, Ng KL, Yoong BK, Choo W1: Predictors of axillary lymph node metastases in breast cancer: is there a role for minimal axillary surgery? World J Surg 2000, 33:54–57.

46. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63:181–187.